tiprankstipranks
Filana Therapeutics, Inc. (DE:PX91)
NASDAQ:PX91
Germany Market
PX91
Filana Therapeutics
RESEARCH TOOLSreports

Filana Therapeutics (PX91) Earnings Dates, Call Summary & Reports

8 Followers

Earnings Data

Report Date
Aug 05, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.19
Last Year’s EPS
-0.8
Same Quarter Last Year
Analyst Consensus
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2024
Earnings Call Date:Nov 07, 2024|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mix of promising progress in clinical trials and financial stability, but also highlighted increased administrative costs and legal challenges. The anticipation of Phase III trial results is a critical point of focus.
Company Guidance
During Cassava Sciences' Q3 2024 earnings call, CEO Richard Barry provided guidance on the company's upcoming milestones and financial outlook. He emphasized the anticipated release of top-line results from the Phase III RETHINK-ALZ trial before the end of the year, highlighting the potential for a best-in-class treatment for Alzheimer's disease. The company plans to report biomarker data for approximately 100 patients, focusing on plasma markers such as pTau 217, Neurofilament Light Chain (NFL), Glial Fibrillary Acidic Protein (GFAP), and total tau. Financially, Cassava Sciences ended the quarter with $149 million in cash, which is expected to be sufficient for operations through the conclusion of ongoing Phase III trials and into 2026. Net cash used in operations for the first nine months of 2024 was $55.7 million, with projections for the second half ranging between $80 million and $90 million, inclusive of a $40 million SEC settlement. The company's net loss for Q3 was $27.9 million, with R&D expenses decreasing as more patients transition to a lower-cost open-label study.
Phase III Trial Progress
Announced the last patient visit for the Phase III trial RETHINK-ALZ, with top-line results expected by the end of the year.
Cash Position and Financial Stability
Ended Q3 with $149 million in cash, expected to fund operations through the conclusion of ongoing Phase III trials and into 2026.
Reduced R&D Expenses
R&D expenses for Q3 were $17.7 million, down from $23.6 million in the same period last year as more patients transition from Phase III to lower-cost open-label studies.
Biomarker Innovation
Discussed the potential of plasma biomarker tests with high correlation to Alzheimer's diagnosis, which could transform treatment by primary care physicians.

Filana Therapeutics (DE:PX91) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

DE:PX91 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2026
2026 (Q2)
-0.19 / -
-0.797―――
May 07, 2026
2026 (Q1)
-0.20 / -0.18
-0.41656.25% (+0.23)――
Mar 12, 2026
2025 (Q4)
-0.26 / -0.23
-0.49454.39% (+0.27)――
Nov 12, 2025
2025 (Q3)
-0.23 / -0.19
-0.50362.07% (+0.31)――
Aug 14, 2025
2025 (Q2)
- / -0.80
0.113-807.69% (-0.91)――
May 08, 2025
2025 (Q1)
- / -0.42
-0.373-11.63% (-0.04)――
Mar 03, 2025
2024 (Q4)
-0.51 / -0.49
-0.433-14.00% (-0.06)――
Nov 07, 2024
2024 (Q3)
-0.63 / -0.50
-0.5294.92% (+0.03)―
Aug 08, 2024
2024 (Q2)
-0.35 / 0.11
-0.546120.63% (+0.66)―
May 10, 2024
2024 (Q1)
-0.40 / -0.37
-0.50325.86% (+0.13)――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DE:PX91 Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 07, 2026
€1.16€1.20+3.81%
Mar 12, 2026
€2.00€1.76-11.89%
Nov 12, 2025
€2.63€2.64+0.46%
Aug 14, 2025
€1.95€1.93-1.28%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Filana Therapeutics, Inc. (DE:PX91) report earnings?
Filana Therapeutics, Inc. (DE:PX91) is schdueled to report earning on Aug 05, 2026, TBA (Confirmed).
    What is Filana Therapeutics, Inc. (DE:PX91) earnings time?
    Filana Therapeutics, Inc. (DE:PX91) earnings time is at Aug 05, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Filana Therapeutics, Inc. stock?
          The P/E ratio of Filana Therapeutics is N/A.
            What is DE:PX91 EPS forecast?
            DE:PX91 EPS forecast for the fiscal quarter 2026 (Q2) is -0.19.